Phase 1 Clinical Trial Confirms HIV Vaccine Approach
by Angela Mohan on
February 4, 2021 at 11:12 AM
Phase 1 clinical trial testing a novel vaccine against HIV has produced promising results, IAVI and Scripps Research announced. The vaccine showed success in stimulating production of rare immune cells needed to start the process of generating antibodies against the fast-mutating virus; the targeted response was detected in 97 percent of participants who received the vaccine.
"This study demonstrates proof of principle for a new vaccine concept for HIV, a concept that could be applied to other pathogens, as well," says William Schief, Ph.D., a professor and immunologist at Scripps Research and executive director of vaccine design at IAVI's Neutralizing Antibody Center, whose laboratory developed the vaccine.